Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BGI and GT Life Sciences Sequence Chinese Hamster Ovary Genome

publication date: Aug 2, 2011
BGI, the giant genomics institute located in Shenzhen, and GT Life Sciences of San Diego have published their collaborative study on the genomic sequence of the Chinese hamster ovary (CHO) K1 cell line in Nature Biotechnology. Over 70% of the recombinant therapeutic proteins sold today are manufactured using mammalian cells, primarily CHO cell lines. GT Life Sciences uses a metabolic modeling platform to design new products and processes for the life sciences field. It says a better understanding of the genome will speed development of new recombinant protein therapies. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital